Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer. - McLaughlin S; Nakajima E; Bar Y; Hutchinson JA; Shin J; Moy B; Isakoff SJ; Bardia A; Kuter I; Spring LM (Therapeutic advances in medical oncology, 2023)